Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh developed a new way to profile brain cancers in children, paving ...

Researchers at the University of Houston, in collaboration with Baylor College of Medicine, are developing new devices for ...

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy ...